Results from a phase 1 study investigating the safety and pharmacokinetics of the aldosterone synthase inhibitor baxdrostat in subjects with varying degrees of hepatic function

被引：0

作者：

Hui, James ^{[1
]}

Halvorsen, Yuan-Di ^{[1
]}

Bond, Mary ^{[2
]}

Murphy, Brian ^{[2
]}

Isaacsohn, Jonathan ^{[2
]}

Freeman, Mason W. ^{[1
]}

机构：

[1] CinCor Pharma Inc, Waltham, MA USA

[2] CinRx Pharma LLC, Cincinnati, OH USA

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

P0061

引用

页码：246 / 247

页数：2

共 50 条

[21] Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function
Mayer M.
Nudurupati S.
Peng X.
Marcinak J.
Drugs in R&D, 2014, 14 (4) : 273 - 282
[22] Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies
Uchiyama, Makoto
Mishima, Kazuo
Yagi, Tomoko
Yoshihara, Tatsuya
Eto, Takashi
Muehlan, Clemens
Togo, Osamu
Inoue, Yuichi
JOURNAL OF SLEEP RESEARCH, 2025, 34 (01)
[23] A phase I study evaluating the pharmacokinetics of components of S-1 in pts with varying degrees of renal function
Saif, M. W.
Lichinitser, M.
Gordon, M. S.
Tan, B. R.
Scheulen, M. E.
Pandya, N. B.
Sarantopoulos, J.
Rinehart, J. J.
Verschraegen, C. F.
Lenz, H.
Zergebel, C.
Saito, K.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[24] Evaluation of safety, tolerability and pharmacokinetics (PK) of patupilone in patients (pts) with advanced solid tumors and varying degrees of hepatic function: An open-label phase I study
Reid, T. R.
Takimoto, C. H.
Verschraegen, C. F.
Sarantopoulos, J.
Cheung, W.
Allen-Freda, E.
Li, J.
Xu, Y.
Ko, J.
Johri, A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[25] Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects
Flanagan, Shawn
Ong, Voon
Marbury, Thomas
Jandourek, Alena
Gandhi, Ronak G.
Sandison, Taylor
PHARMACOTHERAPY, 2024, 44 (06): : 435 - 443
[26] First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
Shimizu, Hidetoshi
Tortorici, Michael A.
Ohta, Yoshiyasu
Ogawa, Kei
Rahman, Sheikh Mohammed Ashfaq
Fujii, Aya
Hiraga, Yuki
Kawai, Mizue
Sugimoto-Kawabata, Kanami
van Iersel, Mattheus
van Lier, Jan Jaap
Djedjos, Stephen
Slingsby, B. T.
Rodman, David M.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (08):
[27] A Phase I Clinical Study of the Pharmacokinetics and Safety of Prusogliptin Tablets in Subjects with Mild to Moderate Hepatic Insufficiency and Normal Liver Function
Zhang, Huiting
Bian, Yicong
Zhao, Weifeng
Miao, Liyan
Zhang, Hua
Cui, Juanjuan
Zhang, Xiaofang
Zhang, Xueyuan
Cai, Wen
CURRENT DRUG METABOLISM, 2024, 25 (02) : 140 - 151
[28] Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
Dymond, Angela W.
Martin, Paul
So, Karen
Huang, Yifan
Severin, Paul
Holmes, Victoria
Mariani, Gabriella
Marbury, Thomas
JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (05): : 592 - 605
[29] Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function
Swan, SK
Baker, JF
Free, R
Tucker, RM
Barron, B
Barr, R
Seltzer, S
Gazelle, GS
Maravilla, KR
Barr, W
Stevens, GR
Lambrecht, LJ
Pierro, JA
JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1999, 9 (02): : 317 - 321
[30] Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects
Griffith, David C.
Loutit, Jeffery S.
Morgan, Elizabeth E.
Durso, Stephanie
Dudley, Michael N.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (10) : 6326 - 6332

← 1 2 3 4 5 →